129 related articles for article (PubMed ID: 35373021)
41. Adherence to phosphate binder therapy is the primary determinant of hyperphosphatemia incidence in patients receiving peritoneal dialysis.
Hung KY; Liao SC; Chen TH; Chao MC; Chen JB
Ther Apher Dial; 2013 Feb; 17(1):72-7. PubMed ID: 23379497
[TBL] [Abstract][Full Text] [Related]
42. Phosphorus Counting Table for the control of serum phosphorus levels without phosphate binders in hemodialysis patients.
Bertonsello-Catto VR; Lucca LJ; da Costa JAC
Clin Nutr ESPEN; 2019 Aug; 32():153-157. PubMed ID: 31221281
[TBL] [Abstract][Full Text] [Related]
43. Effect of gastric acid suppression with pantoprazole on the efficacy of calcium carbonate as a phosphate binder in haemodialysis patients.
Cervelli MJ; Shaman A; Meade A; Carroll R; McDonald SP
Nephrology (Carlton); 2012 Jul; 17(5):458-65. PubMed ID: 22471559
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of calcium acetate-magnesium carbonate in the treatment of hyperphosphatemia in dialysis patients.
Helal I; Elkateb H; Hedri H; Hajri M; Hamida FB
Saudi J Kidney Dis Transpl; 2016; 27(6):1162-1167. PubMed ID: 27900961
[TBL] [Abstract][Full Text] [Related]
45. Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study.
Lee YK; Choi HY; Shin SK; Lee HY
Clin Nephrol; 2013 Feb; 79(2):136-42. PubMed ID: 23211335
[TBL] [Abstract][Full Text] [Related]
46. Self-adjustment of phosphate binder dose to meal phosphorus content improves management of hyperphosphataemia in children with chronic kidney disease.
Ahlenstiel T; Pape L; Ehrich JH; Kuhlmann MK
Nephrol Dial Transplant; 2010 Oct; 25(10):3241-9. PubMed ID: 20308040
[TBL] [Abstract][Full Text] [Related]
47. Iron-magnesium hydroxycarbonate (fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients.
McIntyre CW; Pai P; Warwick G; Wilkie M; Toft AJ; Hutchison AJ
Clin J Am Soc Nephrol; 2009 Feb; 4(2):401-9. PubMed ID: 19158369
[TBL] [Abstract][Full Text] [Related]
48. Hyperphosphatemia and phosphate binders: effectiveness and safety.
Kalaitzidis RG; Elisaf MS
Curr Med Res Opin; 2014 Jan; 30(1):109-12. PubMed ID: 24007207
[TBL] [Abstract][Full Text] [Related]
49. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
Prajapati VA; Galani VJ; Shah PR
Saudi J Kidney Dis Transpl; 2014 May; 25(3):530-8. PubMed ID: 24821148
[TBL] [Abstract][Full Text] [Related]
50. MgCaCO3 versus CaCO3 in peritoneal dialysis patients--a cross-over pilot trial.
Evsanaa B; Liu I; Aliazardeh B; Mahdavi S; Bajwa G; Gula J; Tam M; Sze E; Roscoe JM; Tam PY; Sikaneta T
Perit Dial Int; 2015; 35(1):31-4. PubMed ID: 24584605
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
Shaheen FA; Akeel NM; Badawi LS; Souqiyyeh MZ
Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
[TBL] [Abstract][Full Text] [Related]
52. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis.
Jamal SA; Vandermeer B; Raggi P; Mendelssohn DC; Chatterley T; Dorgan M; Lok CE; Fitchett D; Tsuyuki RT
Lancet; 2013 Oct; 382(9900):1268-77. PubMed ID: 23870817
[TBL] [Abstract][Full Text] [Related]
53. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
[TBL] [Abstract][Full Text] [Related]
54. Phosphate Control: The Next Frontier in Dialysis Cardiovascular Mortality.
McCullough PA
Cardiorenal Med; 2021; 11(3):123-132. PubMed ID: 34120113
[TBL] [Abstract][Full Text] [Related]
55. Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study.
Al-Baaj F; Speake M; Hutchison AJ
Nephrol Dial Transplant; 2005 Apr; 20(4):775-82. PubMed ID: 15703206
[TBL] [Abstract][Full Text] [Related]
56. Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study.
Spiegel DM; Farmer B; Smits G; Chonchol M
J Ren Nutr; 2007 Nov; 17(6):416-22. PubMed ID: 17971314
[TBL] [Abstract][Full Text] [Related]
57. Improvement in Hyperphosphatemia Using Phosphate Education and Planning Talks.
Brauer A; Waheed S; Singh T; Maursetter L
J Ren Nutr; 2019 Mar; 29(2):156-162. PubMed ID: 30087012
[TBL] [Abstract][Full Text] [Related]
58. A 6-Month clinical practice pilot study of sucroferric oxyhydroxide on nutritional status in patients on peritoneal dialysis.
Perez L; You Z; Teitelbaum I; Andrews ES; Reddin R; Ramirez-Renteria L; Wilson G; Kendrick J
BMC Nephrol; 2022 Jul; 23(1):245. PubMed ID: 35810296
[TBL] [Abstract][Full Text] [Related]
59. An update on phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a review of safety profiles.
Ogata H; Takeshima A; Ito H
Expert Opin Drug Saf; 2022 Jul; 21(7):947-955. PubMed ID: 35180026
[TBL] [Abstract][Full Text] [Related]
60. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
